摘要
目的探讨在急诊科经静脉溶栓治疗急性心肌梗塞(AMI)病人的临床效果及安全性。方法AMI患者96例,在急诊科经静脉给予尿激酶(UK)溶栓治疗49例为溶栓组(A组),未溶栓治疗患者47例为未溶栓组(B组),两组治疗除了A组使用UK外,其余治疗两组相同。结果溶栓组住院4周病死率为6.4％(3／47),常规治疗组为21％(12／49),两组有显著性差异(P<0.05)。溶栓组心衰发生率为21％(10／47),未溶栓组为48％(24／49),两组有显著性差异(P<0.05)。溶栓组冠脉再道率为55％(26／47),常规治疗组为14％(7／49)。两组再通率有显著性差异(P<0.05)。溶栓组未见致命性的大出血或脑出血。结论:在急诊科溶栓治疗AMI可提高冠状动脉再通率,减少心力率竭发生,保护心功能降低死亡率,明显改善预后。
Objective To study clinical efficacy of thrombolytic therapy in Emergency Department for acute myocardial infarction(AMI).Methods:96 patients with AMI were divided into two groups.49 patients with AMI received urokinase from intravenous as treatment group.47 patients with AMI didnt receive urokinase from intravenous as control group.Other therapy was same in two groups.Results: Death rate was 6.1% (3/49) in treatment group and 21.3% (10/47) in control group for 4 weeks hospitalization.The rate of heart failure was 16.3% (8/49) in treatment group and 38.3% (18/47) in control group.There were significant differences between two groups ( p < 0.05) above results.Conclusion: Intravenous thrombolysis for patient with AMI could increase the reperfusion rate,reduce heart failure for protecting heart function and death rate,to improve remarkably prognosis.
出处
《川北医学院学报》
CAS
2004年第4期171-172,共2页
Journal of North Sichuan Medical College
关键词
急性心肌梗塞
静脉溶栓疗法
尿激酶
Intruvenous thrombolysis Acute myocardial Infarction urokinase
